Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Microenvironment tailors nTreg structure and function.

Schiavon V, Duchez S, Branchtein M, How-Kit A, Cassius C, Daunay A, Shen Y, Dubanchet S, Colisson R, Vanneaux V, Pruvost A, Roucairol C, Setterblad N, Bouaziz JD, Boissier MC, Semerano L, Graux C, Bensussan A, Burny A, Gallo R, Zagury D, Le Buanec H.

Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6298-6307. doi: 10.1073/pnas.1812471116. Epub 2019 Mar 7.

2.

Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.

Fouts TR, Bagley K, Prado IJ, Bobb KL, Schwartz JA, Xu R, Zagursky RJ, Egan MA, Eldridge JH, LaBranche CC, Montefiori DC, Le Buanec H, Zagury D, Pal R, Pavlakis GN, Felber BK, Franchini G, Gordon S, Vaccari M, Lewis GK, DeVico AL, Gallo RC.

Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):E992-9. doi: 10.1073/pnas.1423669112. Epub 2015 Feb 13. Erratum in: Proc Natl Acad Sci U S A. 2015 May 5;112(18):E2413.

3.

[Anti-viral treatment: pro or cons type I IFN?].

Whitehead P, Drouet B, Zagury D, Bensussan A.

Med Sci (Paris). 2013 Oct;29(10):836-9. doi: 10.1051/medsci/20132910008. Epub 2013 Oct 18. French. No abstract available.

4.

[Update on the use of active anti-cytokine therapies with kinoid vaccines for the treatment of inflammatory diseases].

Bouaziz JD, Buanec HL, Zagury D, Bagot M, Bensussan A.

Med Sci (Paris). 2013 Jun-Jul;29(6-7):669-70. doi: 10.1051/medsci/2013296023. Epub 2013 Jul 12. French. No abstract available.

5.

Active and passive anticytokine immune therapies: current status and development.

Le Buanec H, Bensussan A, Bagot M, Gallo RC, Zagury D.

Adv Immunol. 2012;115:187-227. doi: 10.1016/B978-0-12-394299-9.00007-2. Review.

PMID:
22608260
6.

IFN-α and CD46 stimulation are associated with active lupus and skew natural T regulatory cell differentiation to type 1 regulatory T (Tr1) cells.

Le Buanec H, Gougeon ML, Mathian A, Lebon P, Dupont JM, Peltre G, Hemon P, Schmid M, Bizzini B, Künding T, Burny A, Bensussan A, Amoura Z, Gallo RC, Zagury D.

Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):18995-9000. doi: 10.1073/pnas.1113301108. Epub 2011 Nov 7.

7.

Kinoids: a family of immunogens for active anticytokine immunotherapy applied to autoimmune diseases and cancer.

Bizzini B, Drouet B, Zagury D, Abitbol M, Burny A, Boissier MC.

Immunotherapy. 2010 May;2(3):347-65. doi: 10.2217/imt.10.16. Review.

PMID:
20635900
8.

Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis.

Delavallée L, Semerano L, Assier E, Vogel G, Vuagniaux G, Laborie M, Zagury D, Bessis N, Boissier MC.

Arthritis Res Ther. 2009;11(6):R195. doi: 10.1186/ar2897. Epub 2009 Dec 23.

9.

IFNalpha kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model.

Zagury D, Le Buanec H, Mathian A, Larcier P, Burnett R, Amoura Z, Emilie D, Peltre G, Bensussan A, Bizzini B, Gallo RC, Koutouzov S.

Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5294-9. doi: 10.1073/pnas.0900615106. Epub 2009 Mar 11.

10.

Unsung hero Robert C. Gallo.

Abbadessa G, Accolla R, Aiuti F, Albini A, Aldovini A, Alfano M, Antonelli G, Bartholomew C, Bentwich Z, Bertazzoni U, Berzofsky JA, Biberfeld P, Boeri E, Buonaguro L, Buonaguro FM, Bukrinsky M, Burny A, Caruso A, Cassol S, Chandra P, Ceccherini-Nelli L, Chieco-Bianchi L, Clerici M, Colombini-Hatch S, de Giuli Morghen C, de Maria A, de Rossi A, Dierich M, Della-Favera R, Dolei A, Douek D, Erfle V, Felber B, Fiorentini S, Franchini G, Gershoni JM, Gotch F, Green P, Greene WC, Hall W, Haseltine W, Jacobson S, Kallings LO, Kalyanaraman VS, Katinger H, Khalili K, Klein G, Klein E, Klotman M, Klotman P, Kotler M, Kurth R, Lafeuillade A, La Placa M, Lewis J, Lillo F, Lisziewicz J, Lomonico A, Lopalco L, Lori F, Lusso P, Macchi B, Malim M, Margolis L, Markham PD, McClure M, Miller N, Mingari MC, Moretta L, Noonan D, O'Brien S, Okamoto T, Pal R, Palese P, Panet A, Pantaleo G, Pavlakis G, Pistello M, Plotkin S, Poli G, Pomerantz R, Radaelli A, Robertguroff M, Roederer M, Sarngadharan MG, Schols D, Secchiero P, Shearer G, Siccardi A, Stevenson M, Svoboda J, Tartaglia J, Torelli G, Tornesello ML, Tschachler E, Vaccarezza M, Vallbracht A, van Lunzen J, Varnier O, Vicenzi E, von Melchner H, Witz I, Zagury D, Zagury JF, Zauli G, Zipeto D.

Science. 2009 Jan 9;323(5911):206-7. doi: 10.1126/science.323.5911.206. No abstract available.

PMID:
19131607
11.

[Kinoids: a novel generation of specific immune therapy against cytokines].

Bensussan A, Bizzini B, Pouletty P, Gallo RC, Zagury D.

Med Sci (Paris). 2008 Mar;24(3):306-13. doi: 10.1051/medsci/2008243306. Review. French.

12.

Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha.

Delavallée L, Le Buanec H, Bessis N, Assier E, Denys A, Bizzini B, Zagury D, Boissier MC.

Ann Rheum Dis. 2008 Sep;67(9):1332-8. Epub 2007 Nov 27.

PMID:
18042641
13.

Control of allergic reactions in mice by an active anti-murine IL-4 immunization.

Le Buanec H, Paturance S, Couillin I, Schnyder-Candrian S, Larcier P, Ryffel B, Bizzini B, Bensussan A, Burny A, Gallo R, Zagury D, Peltre G.

Vaccine. 2007 Oct 10;25(41):7206-16. Epub 2007 Aug 3.

PMID:
17719148
14.

VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases.

Rad FH, Le Buanec H, Paturance S, Larcier P, Genne P, Ryffel B, Bensussan A, Bizzini B, Gallo RC, Zagury D, Uzan G.

Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2837-42. Epub 2007 Feb 14.

15.

TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation.

Le Buanec H, Delavallée L, Bessis N, Paturance S, Bizzini B, Gallo R, Zagury D, Boissier MC.

Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19442-7. Epub 2006 Dec 8.

16.

Non-toxic immunogens for therapeutic anticytokine vaccines.

Zagury D, Le Buanec H, Bizzini B, Gallo RC.

IDrugs. 2001 Oct;4(10):1161-6.

PMID:
15957085
17.
18.

Anti-cytokine Ab immune therapy: present status and perspectives.

Zagury D, Gallo RC.

Drug Discov Today. 2004 Jan 15;9(2):72-81. Review.

PMID:
15012931
19.

Therapeutic vaccine to control stromal tumor-induced immunosuppression in human uterine cervixc cancer.

Le Buanec H, Cohen L, Paturance S, Burny A, Gallo RC, Zagury D.

Cell Mol Biol (Noisy-le-grand). 2003 Jun;49(4):667-71.

PMID:
12899461
20.

Active versus passive anti-cytokine antibody therapy against cytokine-associated chronic diseases.

Zagury D, Le Buanec H, Bizzini B, Burny A, Lewis G, Gallo RC.

Cytokine Growth Factor Rev. 2003 Apr;14(2):123-37. Review.

PMID:
12651224
21.

Targeting Tat and IFN(alpha) as a therapeutic AIDS vaccine.

Gallo RC, Burny A, Zagury D.

DNA Cell Biol. 2002 Sep;21(9):611-8.

PMID:
12396603
22.

Selective activation of cervical microvascular endothelial cells by human papillomavirus 16-e7 oncoprotein.

D'Anna R, Le Buanec H, Alessandri G, Caruso A, Burny A, Gallo R, Zagury JF, Zagury D, D'Alessio P.

J Natl Cancer Inst. 2001 Dec 19;93(24):1843-51.

PMID:
11752008
23.

Induction in mice of anti-Tat mucosal immunity by the intranasal and oral routes.

Le Buanec H, Vetu C, Lachgar A, Benoit MA, Gillard J, Paturance S, Aucouturier J, Gane V, Zagury D, Bizzini B.

Biomed Pharmacother. 2001 Jul;55(6):316-20.

PMID:
11478583
24.

Toward a new generation of vaccines: the anti-cytokine therapeutic vaccines.

Zagury D, Burny A, Gallo RC.

Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8024-9.

25.

Human papillomavirus-16-E7 oncoprotein enhances the expression of adhesion molecules in cervical endothelial cells but not in human umbilical vein endothelial cells.

D'Anna R, Le Buanec H, Bizzini B, Burny A, Giannouli C, Zagury JF, Gallo RC, Zagury D, D'Alessio P.

J Hum Virol. 2001 Mar-Apr;4(2):85-95.

PMID:
11437318
26.

Validation of genetic case-control studies in AIDS and application to the CX3CR1 polymorphism.

Hendel H, Winkler C, An P, Roemer-Binns E, Nelson G, Haumont P, O'Brien S, Khalilli K, Zagury D, Rappaport J, Zagury JF.

J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):507-11.

PMID:
11391174
27.

Patterns of genomic sequence diversity among their simian immunodeficiency viruses suggest that L'Hoest monkeys (Cercopithecus lhoesti) are a natural lentivirus reservoir.

Beer BE, Bailes E, Dapolito G, Campbell BJ, Goeken RM, Axthelm MK, Markham PD, Bernard J, Zagury D, Franchini G, Sharp PM, Hirsch VM.

J Virol. 2000 Apr;74(8):3892-8.

28.

Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques.

Pauza CD, Trivedi P, Wallace M, Ruckwardt TJ, Le Buanec H, Lu W, Bizzini B, Burny A, Zagury D, Gallo RC.

Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3515-9.

29.

IFN-alpha 2b reduces IL-2 production and IL-2 receptor function in primary CD4+ T cells.

Zella D, Romerio F, Curreli S, Secchiero P, Cicala C, Zagury D, Gallo RC.

J Immunol. 2000 Mar 1;164(5):2296-302.

30.

HPV-16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes.

Le Buanec H, D'Anna R, Lachgar A, Zagury JF, Bernard J, Ittelé D, d'Alessio P, Hallez S, Giannouli C, Burny A, Bizzini B, Gallo RC, Zagury D.

Biomed Pharmacother. 1999 Oct;53(9):424-31.

PMID:
10554678
31.

Induction of cellular immunosuppression by the human papillomavirus type 16 E7 oncogenic protein.

Le Buanec H, Lachgar A, D'Anna R, Zagury JF, Bizzini B, Bernard J, Ittelé D, Hallez S, Giannouli C, Burny A, Zagury D.

Biomed Pharmacother. 1999 Aug;53(7):323-8.

PMID:
10472433
32.

Lectin production by human T-lymphocytes.

Lachgar A, Le Buanec H, Burny A, Bizzini B, Zagury D.

Biomed Pharmacother. 1999 Jun;53(5-6):288-9.

PMID:
10424253
33.

New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS.

Hendel H, Caillat-Zucman S, Lebuanec H, Carrington M, O'Brien S, Andrieu JM, Schächter F, Zagury D, Rappaport J, Winkler C, Nelson GW, Zagury JF.

J Immunol. 1999 Jun 1;162(11):6942-6.

34.

Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum--an adjuvant to antiretroviral tritherapy.

Zagury D, Lecoq H, Gervi I, Le Buanec H, Zagury JF, Bizzini B, Burny A, Hermans P, Perja M, Santagostino E, Gringeri A.

Biomed Pharmacother. 1999 Mar;53(2):90-2.

PMID:
10337463
35.

Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.

Gringeri A, Santagostino E, Muça-Perja M, Mannucci PM, Zagury JF, Bizzini B, Lachgar A, Carcagno M, Rappaport J, Criscuolo M, Blattner W, Burny A, Gallo RC, Zagury D.

J Hum Virol. 1998 May-Jun;1(4):293-8.

PMID:
10195254
36.

Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.

Zagury JF, Sill A, Blattner W, Lachgar A, Le Buanec H, Richardson M, Rappaport J, Hendel H, Bizzini B, Gringeri A, Carcagno M, Criscuolo M, Burny A, Gallo RC, Zagury D.

J Hum Virol. 1998 May-Jun;1(4):282-92.

PMID:
10195253
37.

Tat toxoid as a component of a preventive vaccine in seronegative subjects.

Gringeri A, Santagostino E, Muça-Perja M, Le Buanec H, Bizzini B, Lachgar A, Zagury JF, Rappaport J, Burny A, Gallo RC, Zagury D.

J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 1;20(4):371-5.

PMID:
10096581
38.

Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study).

Gringeri A, Musicco M, Hermans P, Bentwich Z, Cusini M, Bergamasco A, Santagostino E, Burny A, Bizzini B, Zagury D.

J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 1;20(4):358-70.

PMID:
10096580
39.

Binding of HIV-1 to RBCs involves the Duffy antigen receptors for chemokines (DARC).

Lachgar A, Jaureguiberry G, Le Buenac H, Bizzini B, Zagury JF, Rappaport J, Zagury D.

Biomed Pharmacother. 1998;52(10):436-9.

PMID:
9921412
40.

Amplification of the inflammatory cellular redox state by human immunodeficiency virus type 1-immunosuppressive tat and gp160 proteins.

Lachgar A, Sojic N, Arbault S, Bruce D, Sarasin A, Amatore C, Bizzini B, Zagury D, Vuillaume M.

J Virol. 1999 Feb;73(2):1447-52.

41.

Distinctive effects of CCR5, CCR2, and SDF1 genetic polymorphisms in AIDS progression.

Hendel H, Hénon N, Lebuanec H, Lachgar A, Poncelet H, Caillat-Zucman S, Winkler CA, Smith MW, Kenefic L, O'Brien S, Lu W, Andrieu JM, Zagury D, Schächter F, Rappaport J, Zagury JF.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Dec 1;19(4):381-6.

PMID:
9833747
42.

Restoration of immune response by a cationic amphiphilic drug (AY 9944) in vitro: a new approach To chemotherapy against human immunodeficiency virus type 1.

Achour A, Landureau JC, Salerno-Goncalves R, Mazière JC, Zagury D.

Antimicrob Agents Chemother. 1998 Oct;42(10):2482-91. Erratum in: Antimicrob Agents Chemother. 2007 Mar;51(3):1131. Salerno-Concalves, R [corrected to Salerno-Goncalves, R].

43.

C-C chemokines, pivotal in protection against HIV type 1 infection.

Zagury D, Lachgar A, Chams V, Fall LS, Bernard J, Zagury JF, Bizzini B, Gringeri A, Santagostino E, Rappaport J, Feldman M, O'Brien SJ, Burny A, Gallo RC.

Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3857-61.

44.

Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS.

Zagury D, Lachgar A, Chams V, Fall LS, Bernard J, Zagury JF, Bizzini B, Gringeri A, Santagostino E, Rappaport J, Feldman M, Burny A, Gallo RC.

Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3851-6.

45.

A placebo-controlled clinical phase I trial with combined anti-HIV-1 and anti-interferon-alpha immunization.

Coulaud IP, Gougeon ML, Gomard E, Descamps D, Lebon P, Aboulker JP, Bizzini B, Zagury D.

AIDS. 1997 Jun;11(7):937-8. No abstract available.

PMID:
9189226
46.

A naturally unbalanced combat [new; comment].

Zagury D.

Nat Med. 1997 Feb;3(2):156-7. No abstract available.

PMID:
9018232
47.

Potentialization of IL-2 effects on immune cells by oyster extract (JCOE) in normal and HIV-infected individuals.

Achour A, Lachgar A, Astgen A, Chams V, Bizzini B, Tapiero H, Zagury D.

Biomed Pharmacother. 1997;51(10):427-9.

PMID:
9863500
49.

Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report.

Gringeri A, Santagostino E, Cusini M, Muça-Perja M, Marinoni A, Mannucci PM, Burny A, Criscuolo M, Lu W, Andrieru JM, Mbika JP, Lachgar A, Fall LS, Chams V, Feldman M, Hermans P, Zagury JF, Bizzini B, Musicco M, Zagury D.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Sep;13(1):55-67.

PMID:
8797687
50.

Which nutrient supplements for optimal HIV-1 production by cultured human lymphocytes?

Landureau JC, Achour A, Fouchard M, M'Bika JP, Mazière JC, Zagury D.

Cell Mol Biol (Noisy-le-grand). 1995 May;41(3):423-30.

PMID:
7580837

Supplemental Content

Loading ...
Support Center